Suzetrigine Use in the Perioperative Period: A Narrative Review
Authors: Passman, Justin N; Fernandes, Glen; Gritsenko, Karina
Source journal: Current pain and headache reports (2026-11-16)
DOI: 10.1007/s11916-026-01569-2
Abstract
PURPOSE OF REVIEW: Effective perioperative pain management is central to anesthesia and enhanced recovery after surgery protocols. Opioids remain the mainstay for moderate-to-severe postoperative pain, but their adverse effects, including CNS depression and dependency, have driven the search for non-opioid alternatives. Suzetrigine, the first selective NaV1.8 inhibitor approved for moderate-to-severe acute pain in adults, offers a novel mechanism by selectively blocking nociceptive signaling in peripheral sensory neurons and is the first new class of analgesics in decades. RECENT FINDINGS: Phase III trials in patients undergoing abdominoplasty and bunionectomy demonstrated that suzetrigine reduced postoperative pain versus placebo with a favorable safety profile. Efficacy was generally comparable to hydrocodone/acetaminophen, and its opioid-sparing profile makes it an attractive component of multimodal perioperative analgesia. This review summarizes suzetrigine's pharmacology and emerging role in perioperative pain management, emphasizing its integration into multimodal analgesic pathways, opioid-sparing potential, and directions for future study.
Related topics
Related open access articles
- CHALLENGES IN THE DIAGNOSIS AND TREATMENT OF PATIENTS WITH COLORECTAL CANCER AND COVID-19 COINFECTION - CASE REPORT
- Facing COVID-19 via anti-inflammatory mechanism of action: Molecular docking and Pharmacokinetic studies of six anti-inflammatory compounds derived from Passiflora edulis
- Computational analysis by molecular docking of thirty alkaloid compounds from medicinal plants as potent inhibitors of SARS-CoV-2 main protease
- The use of non-invasive ventilation (NIV) in the treatment of patients with COVID-19
- Application of Nanotechnology in Treatment of COVID-19
- Nano Platforms in Combatting COVID-19: Unveiling Antiviral Strategies and Challenges
Abstract and bibliographic data from PubMed (U.S. National Library of Medicine). Copyright of the abstract belongs to the original publisher or authors.